Bristol Myers’ blood cancer drug Breyanzi gets EMA greenlight for earlier use
A panel of the European Medicines Agency (EMA) recommended the expanded approval of Bristol Myers Squibb’s (NYSE:BMY) Breyanzi to treat adult patients with certain types of blood […]
Bristol Myers’ blood cancer drug Breyanzi gets EMA greenlight for earlier use Read More »












